Weight Management
GLP-1 agonists, fat-burning peptides, and lipotropic compounds for metabolic research.
Our weight management peptide collection includes cutting-edge compounds for metabolic research. From GLP-1 receptor agonists to specialized lipotropic agents, each product is selected for research efficacy and quality.
Showing 14 products
Adipotide (FTTP)
Pro-apoptotic peptide that selectively targets vasculature within white adipose tissue, inducing adipocyte death via disruption of blood supply. Studied in
AOD 9604
Modified fragment of human growth hormone (hGH 177-191) with selective lipolytic activity and no reported effect on blood glucose or IGF-1. Studied for adipose
Cagrilintide
Long-acting amylin receptor agonist with a 7-day half-life. Studied for weight management both as monotherapy and in combination with semaglutide (CagriSema).
Cagrisema
Pre-formulated combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Phase 2 data showed 15.6% weight reduction with a favourable
HGH Fragment 176-191
C-terminal fragment of human growth hormone (amino acids 176-191) with potent lipolytic activity. Studied for adipose reduction without the growth-promoting or
L-Carnitine
Conditionally essential amino acid derivative that transports long-chain fatty acids into mitochondria for beta-oxidation. Widely studied for fat metabolism
Lipo-C
Lipotropic injection combining methionine, inositol, and choline (MIC). Promotes hepatic fat metabolism, supports bile production, and is used in weight
Liraglutide
Daily GLP-1 receptor agonist with a 13-hour half-life. SCALE trials at 3mg daily dose showed average weight reductions of 8% over 56 weeks.
Mazdutide
Once-weekly dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics. Phase 2 data in a Chinese population showed up to 11.3% weight reduction
MIC (Lipo-C + B12)
Methionine, Inositol, Choline lipotropic complex enhanced with Vitamin B12 (methylcobalamin). Combines hepatic fat mobilisation with neurological and energy
Retatrutide
Triple GLP-1, GIP, and glucagon receptor agonist. Phase 2 data reported up to 24.2% body weight reduction at 12mg weekly dose over 48 weeks.
Semaglutide
Long-acting GLP-1 receptor agonist. STEP-1 trial reported 14.9% average body weight reduction at 2.4mg weekly dose over 68 weeks.
Survodutide
Dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. Phase 2 data showed 19% weight reduction at the highest dose over 46 weeks.
Tirzepatide
Dual GIP and GLP-1 receptor agonist. Among the most potent metabolic peptides studied to date, with clinical trials reporting up to 21% body weight reduction.